Bath Savings Trust Co Sells 2,669 Shares of Johnson & Johnson (NYSE:JNJ)

Bath Savings Trust Co trimmed its position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 7.4% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 33,245 shares of the company's stock after selling 2,669 shares during the period. Bath Savings Trust Co's holdings in Johnson & Johnson were worth $5,513,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of the business. WealthTrak Capital Management LLC purchased a new stake in Johnson & Johnson in the 4th quarter worth approximately $26,000. Mountain Hill Investment Partners Corp. acquired a new position in shares of Johnson & Johnson during the fourth quarter worth $29,000. Bay Harbor Wealth Management LLC bought a new stake in shares of Johnson & Johnson in the fourth quarter worth $32,000. Conquis Financial LLC acquired a new position in Johnson & Johnson in the fourth quarter worth $33,000. Finally, Bernard Wealth Management Corp. bought a new stake in Johnson & Johnson in the fourth quarter valued at $36,000. Hedge funds and other institutional investors own 69.55% of the company's stock.

Wall Street Analysts Forecast Growth

JNJ has been the topic of several recent research reports. Morgan Stanley lifted their price objective on shares of Johnson & Johnson from $164.00 to $169.00 and gave the stock an "equal weight" rating in a research note on Wednesday, April 16th. Barclays cut their price objective on Johnson & Johnson from $166.00 to $165.00 and set an "equal weight" rating for the company in a research report on Thursday, April 17th. Wall Street Zen cut Johnson & Johnson from a "strong-buy" rating to a "buy" rating in a report on Thursday, May 22nd. Royal Bank of Canada reaffirmed an "outperform" rating and set a $181.00 price objective on shares of Johnson & Johnson in a report on Wednesday, April 16th. Finally, Raymond James lowered their target price on Johnson & Johnson from $165.00 to $162.00 and set an "outperform" rating for the company in a research note on Monday, April 14th. Eleven analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $170.88.

Johnson & Johnson Stock Performance

NYSE:JNJ traded up $1.41 on Friday, reaching $154.99. 15,529,047 shares of the company's stock were exchanged, compared to its average volume of 7,975,488. The stock has a fifty day simple moving average of $154.31 and a 200-day simple moving average of $153.65. The firm has a market cap of $372.92 billion, a price-to-earnings ratio of 23.31, a P/E/G ratio of 2.56 and a beta of 0.42. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.11 and a quick ratio of 0.86. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $169.99.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.59 by $0.18. The business had revenue of $21.89 billion during the quarter, compared to analyst estimates of $21.65 billion. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. As a group, sell-side analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 10th. Shareholders of record on Tuesday, May 27th will be paid a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a yield of 3.36%. This is an increase from Johnson & Johnson's previous quarterly dividend of $1.24. The ex-dividend date of this dividend is Tuesday, May 27th. Johnson & Johnson's dividend payout ratio (DPR) is currently 57.84%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.